Form 4: Moderna Insider Sells Shares

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reported transactions involving the sale of company stock.

Summary

• Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc., reported transactions on June 1, 2026.
• The transactions involved the disposal of 2,165 shares of common stock, acquired through the vesting of restricted stock units.
• Additionally, 1,047 shares were disposed of to cover tax withholding obligations related to the vesting of restricted stock units, at a price of $47.19 per share.
• Following these transactions, Klinger beneficially owns 67,468 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard insider transaction for tax purposes rather than a strategic decision to divest significant holdings.

Negatives

• Insider selling of company stock can sometimes be perceived negatively by the market, although this specific transaction was related to tax withholding obligations.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to insider transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. While sales can sometimes signal a lack of confidence, in this instance, a portion of the sale was explicitly for tax withholding, a common and expected event upon the vesting of equity awards.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may be scrutinized, but the context of tax withholding mitigates significant concern.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding